HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211 | Zendy

Timothy Wilkin | Zendy; Zhaohui Su | Zendy; Daniel R. Kuritzkes | Zendy; Michael D. Hughes | Zendy; Charles Flexner | Zendy; Robert Gross | Zendy; Eoin Coakley | Zendy; Wayne Greaves | Zendy; Catherine Godfrey | Zendy; Paul R. Skolnik | Zendy; J. Timpone | Zendy; Benigno Rodríguez | Zendy; Roy M. Gulick | Zendy

Open Access

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Author(s) -

Timothy Wilkin,

Zhaohui Su,

Daniel R. Kuritzkes,

Michael D. Hughes,

Charles Flexner,

Robert Gross,

Eoin Coakley,

Wayne Greaves,

Catherine Godfrey,

Paul R. Skolnik,

J. Timpone,

Benigno Rodríguez,

Roy M. Gulick

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/511035

Subject(s) - medicine , ccr5 receptor antagonist , viral load , virus , virology , cxcr4 , immunology , chemokine , chemokine receptor , inflammation

Chemokine coreceptor use impacts both the natural history of human immunodeficiency virus type 1 (HIV-1) disease and the potential use of a new class of antiretroviral agents, the CCR5 inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research